SCHEMBL19083787

SCHEMBL19083787

CC(C)(C)C1CCN(Cc2cc(C(F)(F)F)ccc2F)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DCUN1D1 Q96GG9 2/20 0.43
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
IDO1 P14902 1/20 0.41
MGAT2 Q10469 1/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39
UBE2M P61081 1/20 0.39
CYP3A4 P08684 1/20 0.39
POLB P06746 1/20 0.39
MTNR1B P49286 1/20 0.39
ACKR3 P25106 1/20 0.39
KCNH2 Q12809 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
MAOA P21397 1/20 0.38
CACNA1B Q00975 1/20 0.38
DRD2 P14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19083786 0.86 ACHE (0.47) DCUN1D1ALOX5APFEN1IDO1ACHE
SCHEMBL21075531 0.83 ALOX5AP (0.56) DCUN1D1ALOX5APFEN1IDO1MAOA
SCHEMBL19075602 0.83 PDE2A (0.43) MGAT2MTNR1BACKR3
SCHEMBL20697685 0.83 ALOX5AP (0.44) DCUN1D1ALOX5APFEN1IDO1UBE2M
SCHEMBL19084092 0.79 SCN9A (0.42) DCUN1D1MGAT2BCHEACHEBACE1
SCHEMBL13374344 0.79 ATM (0.58) ACHEPOLBDRD2
SCHEMBL13374368 0.76 KDM4E (0.60) BCHEACHEBACE1KCNH2MAOA
SCHEMBL13374352 0.74 ALDH1A1 (0.59) MGAT2ACHEMAOADRD2
SCHEMBL19075613 0.73 MGAT2 (0.45) DCUN1D1MGAT2BCHEACHEBACE1
SCHEMBL1021367 0.73 CXCR3 (0.40) DCUN1D1ALOX5APFEN1CYP3A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005724-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2018-06-26 US disclosed
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 DCUN1D1 3112/4885ALOX5AP 1704/4885FEN1 4305/4885
US-10005724-B2 Therapeutic compounds and methods of use thereof RDX, C1R, MTX1 DCUN1D1 3112/4885ALOX5AP 1704/4885FEN1 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.